Compare Nasdaq Inc (NDAQ) vs Zoetis Inc (ZTS) Price & Performance

Nasdaq IncTrade

Zoetis IncTrade

Price performance (Past 24H)

Key statistics

Nasdaq Inc vs Zoetis Inc — how do they compare? Nasdaq Inc trades at $90.25 (market cap $51.96B), while Zoetis Inc trades at $76.07 (market cap $31.95B). The key difference: Nasdaq Inc is the larger of the two by market cap, and Zoetis Inc pays the higher dividend (2.78%). Which is the better fit depends on your goals.

	NDAQ	ZTS
Market Cap	$51.96B	$31.95B
Sector	Financials	Health
52-Week High	$100.98	$156.76
52-Week Low	$76.85	$71.91
Enterprise Value	$59.02B	$39.24B
Dividend Yield	1.22%	2.78%

View details →View details →

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

NDAQ

US stock indices bounce on technical support amid earnings season uncertainty.FXEmpire · 12 hours agoNeutral Nasdaq Private Market acquires Nasdaq Fund Secondaries to expand private market liquidity platform.GlobeNewsWire · 12 hours agoBullish Georgia's top 5 banks adopt Nasdaq Calypso platform to modernize treasury infrastructure.GlobeNewsWire · 1 day agoBullish View details →

ZTS

Class action lawsuits filed against CALX, AVAV, ZTS, and LCID over alleged misleading statements.GlobeNewsWire · 4 days agoBearish View details →

About Nasdaq Inc

Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.

About Zoetis Inc

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.